1[1]Eckel RH. Obesity and heart disease[J]. Circulation,1997,96(9) :3248 - 3250.
2[2]Meigs J, Nathan D, Wilson P, et al. Metabolic risk factors worsencontinuously across the spectrum of nondiabetie glucose tolerance[J]. Ann Inter Med, 1998,28(7): 524 - 533.
3[3]Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [J]. N Engl JMed, 1997,337(9) :581 - 588.
4[4]Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity[J]. Med Clin North Am ,2000,84(1) :95 - 102.
6[6]Sjostrom L, Rissanen A, Adersen T, et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weightregain in obese patients[J]. Lancet, 1998, 352 (9123): 167 -173.
7[7]Davidson MH, Hauptman J, DiGirolamo M. Weight control andrisk factors reduction in obese subjects treated for 2 years withorlistat[J]. JAMA, 1999,281(3):235 - 242.
8[8]Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat,a lipase inhibitor,in healthy human volunteers[J]. J Clin Pharmacol, 1995,35 (11):1103 - 1198.
9Orlistat for obesity[J]． The Med letter on Drugs ＆ Ther， 1999， 41(1 055)：55．
10Carek PL． Current concettsin the pharmacol management of obesity[J]． Drugs，1999， 57(6)： 883．
